Results 211 to 220 of about 39,038 (256)

Novel variants of monogenic diabetes and impact of genetic diagnosis on treatment strategies. [PDF]

Front Med (Lausanne)
Stankute I, Cemerkaite A, Leonaviciute G, Sukys M, Aleknaviciene K, Ugenskiene R, Verkauskiene R.   +6 more
europepmc   +1 more source

Monogenic Familial Neonatal Diabetes in Preterm Infant With ABCC8 Gene Mutation: Transition to Oral Sulfonylurea Therapy. [PDF]

J Pediatr Pharmacol Ther
Behre E, Donnell SS, Larsen N, Mora G, Patra K.   +4 more
europepmc   +1 more source

Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4. [PDF]

Diabetes
Pearson ER, Del Prato S, Pavo I, Franco DR, Zheng J, Nicolay C, Hemmingway A, Wiese RJ, Kahn SE.   +8 more
europepmc   +1 more source

SGLT2 inhibitors for primary prevention of macrovascular and major microvascular complications in type 2 diabetes: an island-wide cohort study. [PDF]

J R Soc Med
Cheng WY, Yen FS, Hung YM, Wei JC, Lin HJ, Huang YH, Hsu CC, Hwu CM.   +7 more
europepmc   +1 more source

Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk. [PDF]

J Am Heart Assoc
Deng Y, Polley EC, Herrin J, Swarna KS, Kent DM, Ross JS, Maron BA, Mickelson MM, McCoy RG.   +8 more
europepmc   +1 more source

Glucagon-like Peptide-1 Receptor Agonists in Asthma Exacerbations: An Application of High-Dimensional Iterative Causal Forest to Identify Subgroups. [PDF]

Pharmacoepidemiol Drug Saf
Wang T, Wang JH, Kinlaw AC, Wyss R, Pate V, Gou Z, Buse JB, Keet CA, Kosorok MR, Stürmer T.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sulfonylurea receptors and mechanism of sulfonylurea action

Experimental and Clinical Endocrinology & Diabetes, 2009
Binding of hypoglycemic sulfonylureas and their analogues to the sulfonylurea receptor in the beta-cell plasma membrane mediates closure of the ATP-sensitive K+-channel (KATP-channel) and thereby stimulation of insulin release. The sulfonylurea receptor is a member of the traffic ATPase family with two intracellular nucleotide binding folds.
U, Panten, M, Schwanstecher, C, Schwanstecher   +2 more
openaire   +2 more sources

SULFONYLUREAS

Endocrinology and Metabolism Clinics of North America, 1997
Sulfonylureas have been available for the treatment of non-insulin-dependent diabetes mellitus (NIDDM) since the 1950s. With the introduction of new oral agents, there is a tendency to discount the value of sulfonylurea therapy. Sulfonylureas have the advantage of multiple formulations, low costs, minimal side effects, and demonstrated efficacy in ...
openaire   +2 more sources